I agree that this site is using cookies. You can find further informations here.
X
Lycke, J.
1173  results:
Search for persons X
?
1

Serum neurofilament light for detecting disease activity in..:

Johnsson, M ; Stenberg, YT ; Farman, HH...
Multiple Sclerosis Journal.  30 (2024)  6 - p. 664-673 , 2024
Link: https://doi.org/10.1177/..
 
?
2

Effectiveness of first generation disease-modifying therapy..:

Tedeholm, H ; Piehl, F ; Lycke, J...
Multiple Sclerosis and Related Disorders.  68 (2022)  - p. 104220 , 2022
Link: https://doi.org/10.1016/..
 
?
3

NFL and CXCL13 may reveal disease activity in clinically an..:

Novakova, L. ; Axelsson, M. ; Malmeström, C....
Multiple Sclerosis and Related Disorders.  46 (2020)  - p. 102463 , 2020
Link: https://doi.org/10.1016/..
 
?
4

Natalizumab, rituximab and fingolimod as escalation therapy..:

Boremalm, M. ; Juto, A. ; Axelsson, M....
European Journal of Neurology.  26 (2019)  8 - p. 1060-1067 , 2019
Link: https://doi.org/10.1111/..
 
?
5

P.027 Efficacy of a fourth alemtuzumab course in RRMS patie..:

Traboulsee, A ; Alroughani, R ; Boster, A...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  45 (2018)  s2 - p. S23-S23 , 2018
Link: https://doi.org/10.1017/..
 
?
6

A.03 Durable clinical and MRI efficacy of alemtuzumab over ..:

Freedman, MS ; Broadley, S ; Chinea, A...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  45 (2018)  s2 - p. S10-S10 , 2018
Link: https://doi.org/10.1017/..
 
?
7

A nationwide survey of the influence of month of birth on t..:

Eliasdottir, Olöf ; Hildeman, Anders ; Longfils, Marco..
Journal of Neurology.  265 (2017)  1 - p. 108-114 , 2017
Link: https://doi.org/10.1007/..
 
?
8

Guidelines for the use of magnetic resonance imaging in dia..:

Vågberg, M. ; Axelsson, M. ; Birgander, R....
Acta Neurologica Scandinavica.  135 (2016)  1 - p. 17-24 , 2016
Link: https://doi.org/10.1111/..
 
?
9

Minocycline added to subcutaneous interferon β‐1a in multip..:

Sørensen, P. S. ; Sellebjerg, F. ; Lycke, J....
European Journal of Neurology.  23 (2016)  5 - p. 861-870 , 2016
Link: https://doi.org/10.1111/..
 
?
10

Rituximab treatment did not aggravate ongoing progressive m..:

Asztely, F. ; Gilland, E. ; Wattjes, M.P..
Journal of the Neurological Sciences.  353 (2015)  1-2 - p. 155-157 , 2015
Link: https://doi.org/10.1016/..
 
?
11

Adverse event profile of alemtuzumab over time in treatment..:

Lycke, J. ; Arnold, D.L. ; Cohen, J.A....
Journal of the Neurological Sciences.  333 (2013)  - p. e374-e375 , 2013
Link: https://doi.org/10.1016/..
 
?
12

Time to secondary progression in patients with multiple scl..:

Tedeholm, H ; Lycke, J ; Skoog, B...
Multiple Sclerosis Journal.  19 (2012)  6 - p. 765-774 , 2012
Link: https://doi.org/10.1177/..
 
?
13

High nationwide prevalence of multiple sclerosis in Sweden:

Ahlgren, C ; Odén, A ; Lycke, J
Multiple Sclerosis Journal.  17 (2011)  8 - p. 901-908 , 2011
Link: https://doi.org/10.1177/..
 
?
14

Glial fibrillary acidic protein: a potential biomarker for ..:

Axelsson, M. ; Malmeström, C. ; Nilsson, S....
Journal of Neurology.  258 (2011)  5 - p. 882-888 , 2011
Link: https://doi.org/10.1007/..
 
?
15

High risk of MS in Iranian immigrants in Gothenburg, Sweden:

Ahlgren, C. ; Lycke, J. ; Odén, A..
Multiple Sclerosis Journal.  16 (2010)  9 - p. 1079-1082 , 2010
Link: https://doi.org/10.1177/..
 
1-15